Research Analysts Offer Predictions for MAZE Q2 Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Stock analysts at HC Wainwright reduced their Q2 2026 EPS estimates for Maze Therapeutics in a research note issued on Wednesday, May 13th. HC Wainwright analyst A. Ghosh now forecasts that the company will earn ($0.65) per share for the quarter, down from their prior forecast of ($0.57). HC Wainwright has a “Buy” rating and a $110.00 price objective on the stock. The consensus estimate for Maze Therapeutics’ current full-year earnings is ($2.63) per share. HC Wainwright also issued estimates for Maze Therapeutics’ Q3 2026 earnings at ($0.63) EPS, Q4 2026 earnings at ($0.65) EPS, FY2026 earnings at ($2.38) EPS, FY2027 earnings at ($2.97) EPS, FY2028 earnings at ($2.66) EPS, FY2029 earnings at ($2.15) EPS and FY2030 earnings at ($0.36) EPS.

Other analysts have also issued reports about the stock. Guggenheim boosted their price target on shares of Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Wedbush boosted their price target on shares of Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research note on Monday, March 16th. JPMorgan Chase & Co. boosted their price target on shares of Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 31st. Finally, Mizuho upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics Stock Down 4.1%

Shares of NASDAQ:MAZE opened at $24.50 on Tuesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. The firm has a market capitalization of $1.36 billion, a PE ratio of -9.68 and a beta of 2.50. The firm’s 50-day moving average is $33.00 and its two-hundred day moving average is $37.92. Maze Therapeutics has a 1 year low of $9.15 and a 1 year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The business had revenue of $20.00 million for the quarter.

Insider Buying and Selling

In other news, insider Atul Dandekar sold 7,500 shares of the business’s stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $25.37, for a total transaction of $190,275.00. Following the completion of the transaction, the insider directly owned 10,503 shares of the company’s stock, valued at approximately $266,461.11. The trade was a 41.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 30,000 shares of the business’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $50.45, for a total value of $1,513,500.00. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 86,938 shares of company stock valued at $3,399,463. Corporate insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in MAZE. Washington University boosted its holdings in Maze Therapeutics by 33.3% in the fourth quarter. Washington University now owns 280,802 shares of the company’s stock valued at $11,634,000 after purchasing an additional 70,121 shares in the last quarter. Mass General Brigham Inc acquired a new position in Maze Therapeutics in the fourth quarter valued at approximately $9,943,000. ArrowMark Colorado Holdings LLC acquired a new position in Maze Therapeutics in the third quarter valued at approximately $14,135,000. Boothbay Fund Management LLC boosted its holdings in Maze Therapeutics by 365.9% in the third quarter. Boothbay Fund Management LLC now owns 351,875 shares of the company’s stock valued at $9,124,000 after purchasing an additional 276,345 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Maze Therapeutics by 27.1% in the fourth quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock valued at $70,307,000 after purchasing an additional 362,060 shares in the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.